TOP > 外国特許検索 > Porphyrin-metal complexes and oxygen infusions containing the same

Porphyrin-metal complexes and oxygen infusions containing the same

外国特許コード F110005090
整理番号 A051-72US
掲載日 2011年8月19日
出願国 アメリカ合衆国
出願番号 48538102
公報番号 20040157820
公報番号 7125862
出願日 平成14年7月30日(2002.7.30)
公報発行日 平成16年8月12日(2004.8.12)
公報発行日 平成18年10月24日(2006.10.24)
国際出願番号 JP2002007734
国際公開番号 WO2003011866
国際出願日 平成14年7月30日(2002.7.30)
国際公開日 平成15年2月13日(2003.2.13)
優先権データ
  • 特願2001-229341 (2001.7.30) JP
  • 2002WO-JP07734 (2002.7.30) WO
発明の名称 (英語) Porphyrin-metal complexes and oxygen infusions containing the same
発明の概要(英語) (US7125862)
A porphyrin metal complex that can form a stable oxygen complex and acts effectively as an oxygen infusion, which comprises: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general wherein R1 is an alicyclic hydrocarbon group which may contain a substituent, R2 is an alkylene group and R3 is a group which does not hinder the coordination of an imidazolyl group to M.
特許請求の範囲(英語) [claim1]
1. A porphyrin metal complex comprising: a transition metal ion M of period 4 or 5 coordinating to a porphyrin derivative represented by the following general formula [I]
wherein R1 is an alicyclic hydrocarbon group selected from the group consisting of a 1-substituted cyclopropyl group, a 1-substituted cyclopentyl group, a 1-substituted cyclohexyl group, a 1-methyl-2-cyclohexenyl group, a 1-substiuted norbornyl group and a 1-substituted adamatyl group, R2 is an alkylene group and R3 is a group which does not hinder the coordination of an imidazolyl group to M.
[claim2]
2. A porphyrin metal complex represented by the following general formula [II]:
wherein M is a transition metal of period 4 or 5, R1 is an alicyclic hydrocarbon group selected from the group consisting of a 1-substituted cyclopropyl group, a 1-substituted evelopentyl group, a 1-substituted cyclohexyl group, a 1-methyl-2-cyclohexenyl group, a 1-substiuted norbomyl group and a 1-substituted adamatyl group, R2 is an alkylene group, R3 is a group that does not hinder the coordination of the imidazolyl group to M, X31 is a halogen ion and n denotes a number obtained by subtracting 2 from the valence number of M.
[claim3]
3. The porphyrin metal complex of claim 1, wherein R2 is a C2 to C10 alkylene group.
[claim4]
4. The porphyrin metal complex of claim 1, wherein R3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group.
[claim5]
5. The porphyrin metal complex of claim 1, wherein M is Fe or Co.
[claim6]
6. The porphyrin metal complex of claim 5, wherein M is Fe(II) or Fe(III).
[claim7]
7. The porphyrin metal complex of claim 5, wherein M is Co(II).
[claim8]
8. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 1.
[claim9]
9. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 1 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.
[claim10]
10. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 1 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.
[claim11]
11. The porphyrin metal complex of claim 2, wherein R2 is a C2 to C10 alkylene group.
[claim12]
12. The porphyrin metal complex of claim 2, wherein R3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group.
[claim13]
13. The porphyrin metal complex of claim 3, wherein R3 is a hydrogen atom or a substituent selected from the group consisting of a methyl group, an ethyl group and a propyl group.
[claim14]
14. The porphyrin metal complex of claim 2, wherein M is Fe or Co.
[claim15]
15. The porphyrin metal complex of claim 3, wherein M is Fe or Co.
[claim16]
16. The porphyrin metal complex of claim 4, wherein M is Fe or Co.
[claim17]
17. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 2.
[claim18]
18. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 3.
[claim19]
19. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 4.
[claim20]
20. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 5.
[claim21]
21. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 6.
[claim22]
22. An oxygen infusion composition comprising at least two components, at least one of which is a porphyrin metal complex of claim 7.
[claim23]
23. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 2 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.
[claim24]
24. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 3 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.
[claim25]
25. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 4 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.
[claim26]
26. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 5 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.
[claim27]
27. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 6 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.
[claim28]
28. An oxygen infusion composition prepared by incorporating and binding at least the porphyrin metal complex of claim 7 in a phospholipid vesicle, a fatty oil microsphere, albumin or an albumin multimer.
[claim29]
29. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 2 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.
[claim30]
30. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 3 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.
[claim31]
31. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 4 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.
[claim32]
32. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 5 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.
[claim33]
33. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 6 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.
[claim34]
34. An oxygen infusion composition prepared by incorporating at least the porphyrin metal complex of claim 7 into human serum albumin, recombinant human serum albumin, human serum albumin dimer or recombinant human serum albumin dimer.
  • 発明者/出願人(英語)
  • TSUCHIDA EISHUN
  • KOMATSU TERUYUKI
  • MATSUKAWA YASUKO
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
国際特許分類(IPC)
米国特許分類/主・副
  • 514/185
  • 514/15.2
  • 514/397
  • 514/410
  • 534/15
  • 540/145
参考情報 (研究プロジェクト等) CREST Single Molecule and Atom Level Reactions AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close